Lexaria Bioscience (LEXX) Competitors $0.98 -0.03 (-3.17%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.00 (+0.20%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. OTLK, SRZN, CELU, PYXS, BMEA, INCR, PMVP, GNTA, QNTM, and TELOShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Oncobiologics (OTLK), Surrozen (SRZN), Celularity (CELU), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), PMV Pharmaceuticals (PMVP), Genenta Science (GNTA), Quantum Biopharma (QNTM), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors Oncobiologics Surrozen Celularity Pyxis Oncology Biomea Fusion InterCure PMV Pharmaceuticals Genenta Science Quantum Biopharma Telomir Pharmaceuticals Oncobiologics (NASDAQ:OTLK) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Does the media refer more to OTLK or LEXX? In the previous week, Oncobiologics had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Oncobiologics and 1 mentions for Lexaria Bioscience. Oncobiologics' average media sentiment score of 0.63 equaled Lexaria Bioscience'saverage media sentiment score. Company Overall Sentiment Oncobiologics Positive Lexaria Bioscience Positive Which has stronger valuation & earnings, OTLK or LEXX? Lexaria Bioscience has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.91-2.24Lexaria Bioscience$460K41.59-$5.80M-$0.67-1.46 Do institutionals and insiders have more ownership in OTLK or LEXX? 11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend OTLK or LEXX? Oncobiologics currently has a consensus target price of $9.60, indicating a potential upside of 370.59%. Lexaria Bioscience has a consensus target price of $5.00, indicating a potential upside of 411.25%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OTLK or LEXX more profitable? Oncobiologics has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Oncobiologics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -271.12% Lexaria Bioscience -1,849.19%-157.22%-133.69% Which has more volatility and risk, OTLK or LEXX? Oncobiologics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. SummaryLexaria Bioscience beats Oncobiologics on 10 of the 14 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.75M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-1.4621.0428.0720.05Price / Sales41.59284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book3.768.378.665.87Net Income-$5.80M-$55.19M$3.25B$258.55M7 Day Performance3.44%5.89%4.20%2.23%1 Month Performance12.41%17.63%10.82%12.76%1 Year Performance-68.35%5.09%34.70%19.36% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.2459 of 5 stars$0.98-3.2%$5.00+411.2%-67.8%$19.75M$460K-1.467OTLKOncobiologics2.2563 of 5 stars$2.06-5.5%$9.60+366.0%-75.5%$73.18MN/A-2.2620News CoverageSRZNSurrozen2.7641 of 5 stars$8.70+2.6%$38.50+342.5%+5.3%$72.61M$10.65M-0.3580Positive NewsHigh Trading VolumeCELUCelularity0.1408 of 5 stars$3.15+4.0%N/A+3.6%$72.57M$54.22M-1.19220News CoverageUpcoming EarningsPYXSPyxis Oncology2.4157 of 5 stars$1.13flat$9.00+696.5%-64.5%$70M$16.15M-0.7160BMEABiomea Fusion3.2831 of 5 stars$1.83-1.1%$20.10+998.4%-66.8%$69.51MN/A-0.5250Upcoming EarningsINCRInterCure0.661 of 5 stars$1.55+2.0%N/A-34.5%$69.27M$66.28M0.00350Positive NewsPMVPPMV Pharmaceuticals3.167 of 5 stars$1.34+0.8%$5.50+310.4%-11.7%$69.10MN/A-1.1450News CoveragePositive NewsGNTAGenenta Science2.7337 of 5 stars$3.77-0.1%$25.00+564.0%-12.1%$68.95MN/A0.007Positive NewsGap DownQNTMQuantum BiopharmaN/A$23.71+1.5%N/AN/A$67.95MN/A-1.48N/ATELOTelomir Pharmaceuticals2.9162 of 5 stars$2.21-3.1%$15.00+578.7%-43.7%$67.86MN/A-5.261News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies OTLK Competitors SRZN Competitors CELU Competitors PYXS Competitors BMEA Competitors INCR Competitors PMVP Competitors GNTA Competitors QNTM Competitors TELO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
